Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Table 2

Main patient characteristics.

Enrolled patients	43
Median age (range): years	74 (58–82)
≥75 years	21 (48.8%)
ECOG performance status
0	9
1-2	34
Sites of metastases
Bone	26
Bone + prostate cancer	4
Bone + prostate cancer + lymph nodes	4
Bone + lung	3
Prostate cancer + lymph nodes	3
Liver + lymph nodes	2
Prostate cancer + lung	1
Median PSA (range), ng/mL	78 (47–374)
Previous treatment
Prostatectomy	31
Radiotherapy	9
Hormone therapy
1	28
≥2	15
Prior first-line chemotherapy
w-Epirubicin + w-docetaxel	21
3-w Docetaxel + prednisone	15
w-Docetaxel + prednisone	7
Number of chemotherapy regimens
2	43
>2	23
Prior third-line chemotherapy
Docetaxel + prednisone	23
Best response to prior first-line chemotherapy
PSA decline ≥50%	31
Stable disease	7
Progressive disease	5
Baseline pain intensity
0	0
1	8
2	22
3	8
4	5
5	0
Median hemoglobin, g/dL	10.4
Range	7.9–13.8